Invega
Invega is an originator product from Janssen-Cilag AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 130.00 to CHF 173.00 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Janssen-Cilag AG
- ATC code
- N05AX13
- IT group
- 01.05 Neuroleptica
- Active substances
- Paliperidonum
- Preparation type
- Originator product
- On the SL since
- 01/07/2008
- Last price change
- 01/12/2025
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Ret Tabl 3 mg | 28 Stk | CHF 105.00 | CHF 130.00 | 01/07/2008 | B | 7680579610010 |
| Ret Tabl 6 mg | 28 Stk | CHF 105.00 | CHF 130.00 | 01/07/2008 | B | 7680579610034 |
| Ret Tabl 9 mg | 28 Stk | CHF 144.72 | CHF 173.00 | 01/07/2008 | B | 7680579610058 |
Limitation
No limitation is recorded on the SL for this preparation.
More preparations in this group
FAQ
Is Invega covered by Swiss health insurance?
Yes. Invega is on the FOPH Specialities List, so Swiss mandatory health insurance reimburses it within the authorised indication. You still pay the deductible and a co-payment of 10 per cent.
What does Invega cost in Switzerland?
The public price is the maximum price set by the FOPH and for Invega ranges from CHF 130.00 to CHF 173.00 per pack. The ex-factory price ranges from CHF 105.00 to CHF 144.72. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages